Analyst Ratings For Heron Therapeutics Inc (NASDAQ:HRTX)
Today, Cantor Fitzgerald reiterated its Buy rating on Heron Therapeutics Inc (NASDAQ:HRTX) with a price target of $50.00.
There are 11 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Heron Therapeutics Inc (NASDAQ:HRTX) is Buy with a consensus target price of $53.90 per share, a potential 111.29% upside.
Some recent analyst ratings include
- 12/31/2018-Heron Therapeutics Inc (NASDAQ:HRTX) had its Buy rating reiterated by Cantor Fitzgerald with a $50.00 price target
- 9/13/2018-Heron Therapeutics Inc (NASDAQ:HRTX) has coverage initiated with a Buy rating and $55.00 price target
- 6/22/2018-Heron Therapeutics Inc (NASDAQ:HRTX) had its Buy rating reiterated by Mizuho with a $41.00 price target
- 6/21/2018-Heron Therapeutics Inc (NASDAQ:HRTX) had its Buy rating reiterated by Cowen with a $54.00 price target
- On 11/2/2018 Kimberly Manhard, VP, sold 494 with an average share price of $30.62 per share and the total transaction amounting to $15,126.28.
- On 10/1/2018 Kimberly Manhard, VP, sold 6,000 with an average share price of $32.07 per share and the total transaction amounting to $192,420.00.
- On 9/12/2018 Kevin C Tang, Director, sold 2,695,000 with an average share price of $35.75 per share and the total transaction amounting to $96,346,250.00.
- On 7/2/2018 Kimberly Manhard, VP, sold 6,000 with an average share price of $37.53 per share and the total transaction amounting to $225,180.00.
- On 7/2/2018 Robert Hoffman, CFO, sold 30,000 with an average share price of $38.17 per share and the total transaction amounting to $1,145,100.00.
- On 7/2/2018 Robert Rosen, President, sold 225,000 with an average share price of $38.98 per share and the total transaction amounting to $8,770,500.00.
- On 6/29/2018 Robert Rosen, President, sold 129,469 with an average share price of $39.59 per share and the total transaction amounting to $5,125,677.71.
About Heron Therapeutics Inc (NASDAQ:HRTX)
Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Recent Trading Activity for Heron Therapeutics Inc (NASDAQ:HRTX)
Shares of Heron Therapeutics Inc closed the previous trading session at 25,54 up +1,79 7,54 % with 24.73 shares trading hands.